Download PDF
CC BY 4.0 · TH Open 2018; 02(04): e399-e406
DOI: 10.1055/s-0038-1675576
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Comparison of ACUITY, CRUSADE, and GRACE Risk Scales for Predicting Clinical Outcomes in Patients Treated with Dual-Antiplatelet Therapy

Sun Young Choi
1   Department of Biomedical Laboratory Science, Daegu Health College, Daegu, Republic of Korea
,
Moo Hyun Kim
2   Department of Cardiology, College of Medicine, Dong-A University, Busan, Republic of Korea
,
Victor Serebruany
3   HeartDrug™ Research Laboratories, Johns Hopkins University, Towson, Maryland, United States
› Author Affiliations Funding This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C1731) and funded by the Ministry of Education, Science and Technology (NNRF-2015R1D1A1A09057025) to M.H.K. Part of this work was supported by the “Brain Pool” program funded by the Korean Ministry of Science and Technology to V.S.
Further Information

Publication History

15 April 2018

17 September 2018

Publication Date:
27 November 2018 (online)

   Permissions and Reprints

Corrected by:

Erratum to: “Comparison of ACUITY, CRUSADE, and GRACE Risk Scales for Predicting Clinical Outcomes in Patients Treated with Dual-Antiplatelet Therapy”TH Open 2019; 03(01): e36-e36
DOI: 10.1055/s-0039-1677685

Abstract

Several reliable scales have been proposed for the management and prognosis in patients with acute coronary syndromes (ACS) treated with dual-antiplatelet therapy (DAPT). We sought to compare the performance of three conventional risk scores to predict major bleeding (MB; such as ACUITY or CRUSADE), or major adverse cardiovascular event (MACE for GRACE). This study included 904 consecutive post-ACS patients from the single Korean study center who underwent coronary interventions, and were treated with DAPT. All three scores were calculated based on admission data. MB and MACE were collected at 30-day and 1-year follow-ups. MB was defined according to the Bleeding Academic Research Consortium (BARC) criteria (types 3–5), and MACE included all-cause death, myocardial infarction, target vessel revascularization, and stroke. MB occurred in 114 patients (12.6%) during 30 days, and 65 patients (7.2%) from 30 days till 1-year follow-up. MACE occurred in 28 (3.1%) and 72 (8.0%) patients during 30 and 30 days till 1 year, respectively. For 30 days MB, the discriminatory ability of ACUITY (AUC: 0.83, 95% CI: 0.81–0.86) and CRUSADE (AUC: 0.82, 95% CI: 0.79–0.84) was similar, and more reliable than GRACE (AUC: 0.74, 95% CI: 0.71–0.77; p < 0.0001 and p = 0.002, respectively). The predictive value for 1-year MB was similar between ACUITY (AUC: 0.75, 95% CI: 0.72–0.78, p < 0.0001), CRUSADE (AUC: 0.70, 95% CI: 0.70–0.73, p < 0.0001), and GRACE (AUC: 0.70, 95% CI: 0.67–0.73, p < 0.0001) classifications. All three risk scales exhibited similar prediction for 30-day and 1-year MACE. We conclude that ACUITY and CRUSADE scores were superior to GRACE in predicting 30-day MB. However, all three risk scales were similarly useful for long-term MB, and MACE assessment.

Keywords

ACUITY - CRUSADE - GRACE - ACS - risk score - bleeding - dual-antiplatelet therapy
 

  • References

  • 1 Montalescot G, Brieger D, Dalby AJ, Park SJ, Mehran R. Duration of dual antiplatelet therapy after coronary stenting: a review of the evidence. J Am Coll Cardiol 2015; 66 (07) 832-847
    CrossrefPubMedGoogle Scholar
  • 2 Giustino G, Baber U, Sartori S. , et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2015; 65 (13) 1298-1310
    CrossrefPubMedGoogle Scholar
  • 3 Mehran R, Pocock SJ, Nikolsky E. , et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010; 55 (23) 2556-2566
    CrossrefPubMedGoogle Scholar
  • 4 Subherwal S, Bach RG, Chen AY. , et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 2009; 119 (14) 1873-1882
    CrossrefPubMedGoogle Scholar
  • 5 Granger CB, Goldberg RJ, Dabbous O. , et al; Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163 (19) 2345-2353
    CrossrefPubMedGoogle Scholar
  • 6 Costa F, Tijssen JG, Ariotti S. , et al. Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy. J Am Heart Assoc 2015; 4 (12) e002524
    CrossrefPubMedGoogle Scholar
  • 7 Correia LC, Garcia G, Kalil F. , et al. Prognostic value of TIMI score versus GRACE score in ST-segment elevation myocardial infarction. Arq Bras Cardiol 2014; 103 (02) 98-106
    PubMedGoogle Scholar
  • 8 Bang J, Choi SY, Kim MH, Serebruany V. CRUSADE score is superior to platelet function testing for prediction of bleeding in patients following coronary interventions. EBioMedicine 2017; 21: 213-217
    CrossrefPubMedGoogle Scholar
  • 9 Mehran R, Rao SV, Bhatt DL. , et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedGoogle Scholar
  • 10 Pencina MJ, D'Agostino Sr RB, D'Agostino Jr RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27 (02) 157-172 , discussion 207–212
    CrossrefPubMedGoogle Scholar
  • 11 Núñez E, Steyerberg EW, Núñez J. [Regression modeling strategies]. Rev Esp Cardiol 2011; 64 (06) 501-507
    CrossrefPubMedGoogle Scholar
  • 12 DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44 (03) 837-845
    CrossrefPubMedGoogle Scholar
  • 13 Biancari F, Brascia D, Onorati F. , et al. Prediction of severe bleeding after coronary surgery: the WILL-BLEED Risk Score. Thromb Haemost 2017; 117 (03) 445-456
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Steg PG, Huber K, Andreotti F. , et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32 (15) 1854-1864
    CrossrefPubMedGoogle Scholar
  • 15 Hsieh MJ, Lee CH, Chen CC, Chang SH, Wang CY, Hsieh IC. Predictive performance of HAS-BLED risk score for long-term survival in patients with non-ST elevated myocardial infarction without atrial fibrillation. J Cardiol 2017; 69 (01) 136-143
    PubMedGoogle Scholar
  • 16 Al-Daydamony MM, Farag EM. CRUSADE bleeding score as a predictor of bleeding events in patients with acute coronary syndrome in Zagazig University Hospital. Indian Heart J 2016; 68 (05) 632-638
    CrossrefPubMedGoogle Scholar
  • 17 Garay A, Ariza-Solé A, Abu-Assi E, Lorente V, Sánchez-Salado JC, Cequier Á. Mid term bleeding risk prediction after an acute coronary syndrome: an unsolved question. Rev Esp Cardiol (Engl Ed) 2016; 69 (05) 527-529
    CrossrefPubMedGoogle Scholar
  • 18 Xi S, Zhou S, Wang X. , et al. The performance of CRUSADE and ACUITY bleeding risk scores in ticagrelor-treated ACS patients who underwent PCI. Thromb Haemost 2017; 117 (11) 2186-2193
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Taha S, D'Ascenzo F, Moretti C. , et al. Accuracy of bleeding scores for patients presenting with myocardial infarction: a meta-analysis of 9 studies and 13 759 patients. Postepy Kardiol Interwencyjnej 2015; 11 (03) 182-190
    PubMedGoogle Scholar
  • 20 Food and Drug Administration. Clinical Review on Cancer Risk. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000 MedR.pdf . Assessed April 12, 2018
    PubMed
  • 21 Amador P, Santos JF, Gonçalves S, Seixo F, Soares L. Comparison of ischemic and bleeding risk scores in non-ST elevation acute coronary syndromes. Acute Card Care 2011; 13 (02) 68-75
    CrossrefPubMedGoogle Scholar